We can readily understand why investors are attracted to unprofitable companies. Indeed, Summit Therapeutics (NASDAQ:SMMT) stock is up 347% in the last year, providing strong gains for shareholders.

For good reason (insane, time-enhanced fabrics) MAN-TLE pieces rarely come in under $500, let alone $160. And yet here's some ...

Wednesday marks Autism Awareness Day, a time to promote understanding and acceptance of those with Autism Spectrum Disorder (ASD). Three teens were charged with attempted murder after their ...